Summit Therapeutics (SMMT) FY 2025 Conference June 09, 2025 01:20 PM ET Speaker0 Great. Good afternoon, everyone. Thank you so much for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs. And we're really pleased to be joined by the Summit team who's rather patriotic today. So to start here next to me, have Mickey Zengene, who's Co CEO Bob Duggan, Co CEO Manmeet, Sony, COO and CFO and Dave Genzar's Chief Business Officer. So with that, to start here, could you provide an overview of you ...

New trial arm to evaluate safety, dosing and preliminary anti-tumor activity of the combination therapy in advanced solid tumorsNEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the expansion arm of its Phase 1b/2 clinical trial evaluating Decoy20 in combination with BeOne’s (formerly known as Beigene) PD-1 c ...

Flash | | Price (07 May 25 16:00) | US$232.25 | | --- | --- | | Target price | US$345.00 | | Expected share price return | 48.5% | | Expected dividend yield | 0.0% | | Expected total return | 48.5% | | Market Cap | US$23,004M | Yigal Nochomovitz, Ph.D.AC +1-212-816-1441 yigal.nochomovitz@citi.com 07 May 2025 22:56:30 ET │ 10 pages BeiGene (ONC.O) Well-Positioned for The Long Game. Brukinsa Surpasses Calquence & Imbruvica in US Qtrly Sales, Reiterate Buy CITI'S TAKE The transformation to a global, Swiss-domi ...

Core Insights - BeiGene, Ltd. reported $1.12 billion in revenue for Q1 2025, marking a 48.6% year-over-year increase and an EPS of $1.22 compared to -$2.41 a year ago [1] - The revenue matched the Zacks Consensus Estimate of $1.12 billion, resulting in a slight surprise of -0.65%, while the EPS exceeded expectations with a surprise of +271.83% [1] Financial Performance - Product revenue totaled $1.11 billion, slightly below the estimated $1.12 billion by analysts [4] - Key product revenues included: - BRUKINSA (Zanubrutinib): $791.66 million vs. $820.07 million estimated - Tislelizumab: $171.16 million vs. $171.33 million estimated - XGEVA: $70.42 million vs. $56.55 million estimated - Other: $17.90 million vs. $14.28 million estimated - POBEVCY: $13.75 million vs. $16.11 million estimated - BLINCYTO: $23.91 million vs. $20.42 million estimated - KYPROLIS: $19.73 million vs. $16.51 million estimated - Collaboration revenue was $8.75 million, exceeding the $6.49 million estimate [4] Market Performance - BeiGene's shares have returned +15.4% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Summit Therapeutics (SMMT) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Thank you for standing by. Hello, and welcome to the Summit Therapeutics Q1 twenty twenty five Earnings Conference Call. I would now like to turn the call over to our Chief Business and Strategy Officer, Dave Van Carrs. Please go ahead, sir. Speaker1 Good afternoon, and thank you for joining us. A press release was issued earlier this afternoon and is available on the homepage of our website. Our Form 10 Q was also filed and ...

Summit Therapeutics Inc. SMMT on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 trial, HARMONi-2 or AK112-303.On Friday, Summit Therapeutics stock closed almost 30% lower at around $23.47.HARMONi-2 evaluated monotherapy ivonescimab, PD-1/VEGF bispecific antibody, against monotherapy Merck & Co Inc’s MRK Keytruda (pembrolizumab) in patients with locally ...

Group 1 - Jianyin International raised the target price for Kangfang Biopharma (09926) by 33.3%, from HKD 90 to HKD 120, reflecting improved earnings forecasts and high potential for the company's lung cancer drugs in China and overseas [1] - Kangfang Biopharma's fundamentals are strong, with revenue forecasts for 2025, 2026, and 2027 increased to RMB 3.3 billion, RMB 5.3 billion, and RMB 9.6 billion respectively, and adjusted profit forecasts for 2025, 2026, and 2027 raised to RMB 121 million, RMB 1.2 billion, and RMB 3.9 billion respectively [1] - The approval of Ebdarokimab for moderate to severe plaque psoriasis in China is a significant milestone for Kangfang Biopharma [1] Group 2 - On April 23, Kangfang Biopharma announced that its drug AK112 met the target efficacy in a Phase 3 clinical trial for advanced squamous non-small cell lung cancer, showing superior efficacy compared to Tislelizumab [2] - The independent data monitoring committee confirmed that AK112's efficacy is significantly better than that of Tislelizumab, aligning with previously published Phase 3 clinical data [2] - AK112's performance indicates it outperforms Merck's well-known PD-1 biologic competitor, Keytruda [2]

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity. Jeffrey Mec ...

Core Insights - Indaptus Therapeutics reported significant progress in its Phase 1 trial of Decoy20, with over 20 patients enrolled in the weekly dosing cohort, indicating potential clinical benefits and a favorable safety profile [2][6][7] - The company experienced a decrease in total operating expenses for the fiscal year 2024 compared to 2023, primarily due to reduced research and development costs [4][5][21] - Indaptus has secured new patents in multiple countries and received clinical trial authorization from Health Canada, enhancing its intellectual property and operational capabilities [7][9] Financial Highlights - Research and development expenses for Q4 2024 were $2.5 million, up from $2.0 million in Q4 2023, mainly due to increased costs in the Phase 1 clinical trial [4] - Total operating expenses for the fiscal year 2024 were $15.4 million, a decrease from $16.4 million in 2023, with research and development costs dropping to $7.2 million from $7.6 million [21] - The company reported a net loss of $15.0 million for the fiscal year 2024, compared to a net loss of $15.4 million in 2023, resulting in a loss per share of $1.61, an improvement from $1.83 in the previous year [8][21] Cash Position and Financing - As of December 31, 2024, Indaptus had cash and cash equivalents of $5.8 million, down from $13.4 million at the end of 2023 [9] - The company conducted a private placement in January 2025, generating net proceeds of $2.0 million, and established a $20 million equity line of credit in February 2025 [9] - Net cash used in operating activities for the fiscal year 2024 was $12.3 million, a slight decrease from $13.4 million in 2023 [10][22] Clinical and Corporate Developments - Indaptus is advancing its Phase 1 study of Decoy20 in advanced solid tumors, with plans to initiate a combination trial with BeiGene's PD-1 inhibitor, tislelizumab, expected in 2025 [7][15] - The company presented promising pharmacokinetic and safety results for Decoy20 at major oncology conferences, further validating its clinical approach [7] - Indaptus plans to increase trial sites to accelerate patient enrollment and expects to provide further clinical updates throughout 2025 [15]